These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 8058057

  • 1. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC.
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [Abstract] [Full Text] [Related]

  • 2. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC.
    Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
    [Abstract] [Full Text] [Related]

  • 3. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH.
    Cancer Res; 1994 Jan 01; 54(1):152-8. PubMed ID: 7903202
    [Abstract] [Full Text] [Related]

  • 4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 5. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H, Kohno K, Ono M, Uchida Y, Kuwano M.
    Cancer Res; 1991 Aug 01; 51(15):3951-7. PubMed ID: 1649696
    [Abstract] [Full Text] [Related]

  • 6. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T, Takemura H, Yamashita T, Ishisaka T, Inai K, Imamura S, Urasaki Y, Ueda T.
    Anticancer Res; 1999 Aug 01; 19(6B):5111-5. PubMed ID: 10697518
    [Abstract] [Full Text] [Related]

  • 7. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT.
    Cancer Res; 1993 Mar 15; 53(6):1373-9. PubMed ID: 8383009
    [Abstract] [Full Text] [Related]

  • 8. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 9. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP.
    Cancer Res; 1993 Oct 15; 53(20):4866-73. PubMed ID: 8104687
    [Abstract] [Full Text] [Related]

  • 10. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
    Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF, Sartorelli AC.
    Cancer Res; 1995 Oct 01; 55(19):4352-60. PubMed ID: 7671247
    [Abstract] [Full Text] [Related]

  • 11. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH.
    Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM.
    Cancer Res; 1991 Oct 01; 51(19):5275-83. PubMed ID: 1717144
    [Abstract] [Full Text] [Related]

  • 13. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I.
    J Cell Physiol; 1993 May 01; 155(2):414-25. PubMed ID: 8097746
    [Abstract] [Full Text] [Related]

  • 14. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, Kuwano M.
    Cancer Res; 1995 Sep 01; 55(17):3860-4. PubMed ID: 7641205
    [Abstract] [Full Text] [Related]

  • 15. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
    Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, Krivacic K.
    Mol Pharmacol; 1996 Aug 01; 50(2):243-8. PubMed ID: 8700130
    [Abstract] [Full Text] [Related]

  • 16. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S, Austin CA, Fisher LM.
    Anticancer Drug Des; 1990 Feb 01; 5(1):149-57. PubMed ID: 2156515
    [Abstract] [Full Text] [Related]

  • 17. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH.
    Hiroshima J Med Sci; 1989 Dec 01; 38(4):197-207. PubMed ID: 2561562
    [Abstract] [Full Text] [Related]

  • 18. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G, Lorico A, Sartorelli AC.
    Cancer Res; 1992 May 15; 52(10):2782-90. PubMed ID: 1316227
    [Abstract] [Full Text] [Related]

  • 19. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA.
    Oncol Res; 1995 May 15; 7(1):21-9. PubMed ID: 7549041
    [Abstract] [Full Text] [Related]

  • 20. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC.
    Br J Cancer; 1994 Apr 15; 69(4):687-97. PubMed ID: 8142256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.